In Eli Lilly Canada Inc. v. Apotex Inc., (2024 FCA 72), the Federal Court of Appeal ("FCA") considered the threshold for sufficient disclosure of a patent application in reviewing the decision of the Federal Court that found various claims of Canadian Patent No. 2,226,784 to be invalid.
The appeal centered largely on the definition of a "physiologically acceptable salt of tadalafil" and whether the patent provided sufficient disclosure regarding physiologically acceptable salts of tadalafil.
While the FCA confirmed that a patent specification may be sufficient even if some amount of non-inventive trial and error experimentation is required to re-create the invention, the FCA ultimately upheld the decision of the Federal Court citing evidence that the search for a physiologically acceptable salt of tadalafil requires a lot of experimental work and requires a skilled person to exercise some degree of inventiveness.
A copy of the full decision is available here.
Federal Court Of Appeal Considers Sufficiency Of Disclosure In Patent Applications
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.